Halozyme Therapeutics (HALO) Total Debt (2012 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Total Debt of $2.1 billion for Q1 2026, up 42.27% year-over-year from $1.5 billion in Q1 2025, and little changed quarter-over-quarter from $2.1 billion in Q4 2025.
Halozyme Therapeutics (HALO) Total Debt (2012 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Total Debt for 15 consecutive years, with $2.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 42.27% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $2.1 billion (up 42.27% YoY), while the FY2025 annual figure was $2.1 billion, up 42.29% from the prior year.
- Total Debt steadied at $2.1 billion in Q1 2026 per HALO's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Total Debt topped out at $2.1 billion in Q1 2026 and bottomed at $877.6 million in Q1 2022.
- Historically, Total Debt has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Total Debt jumped 73.32% — and 2023, when it declined 1.33%.
- Halozyme Therapeutics' Total Debt stood at $1.5 billion in 2022, then fell by 1.33% to $1.5 billion in 2023, then increased by 0.44% to $1.5 billion in 2024, then surged by 42.29% to $2.1 billion in 2025, then increased by 0.09% to $2.1 billion in 2026.
- Business Quant data shows HALO's Total Debt at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 2.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Bn |
| Mar 31, 2026 | 2.14 Bn |
| Dec 31, 2025 | 2.14 Bn |
| Sep 30, 2025 | 1.51 Bn |
| Jun 30, 2025 | 1.51 Bn |
| Mar 31, 2025 | 1.51 Bn |
| Dec 31, 2024 | 1.51 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.50 Bn |
| Mar 31, 2024 | 1.50 Bn |
| Dec 31, 2023 | 1.50 Bn |
| Sep 30, 2023 | 1.50 Bn |
| Jun 30, 2023 | 1.50 Bn |
| Mar 31, 2023 | 1.49 Bn |
| Dec 31, 2022 | 1.52 Bn |
| Sep 30, 2022 | 1.52 Bn |
| Jun 30, 2022 | 1.25 Bn |
| Mar 31, 2022 | 877.65 Mn |
| Dec 31, 2021 | 876.67 Mn |
| Sep 30, 2021 | 875.71 Mn |